{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T18:58:00Z","timestamp":1777316280803,"version":"3.51.4"},"reference-count":81,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["medical-hypotheses.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.mehy.2015.01.014","type":"journal-article","created":{"date-parts":[[2015,1,24]],"date-time":"2015-01-24T22:52:24Z","timestamp":1422139944000},"page":"305-314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Biome depletion in conjunction with evolutionary mismatches could play a role in the etiology of neurofibromatosis 1"],"prefix":"10.1016","volume":"84","author":[{"given":"Donna L.","family":"Beales","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2015.01.014_b0005","unstructured":"Neurofibromatosis fact sheet. National Institute of Health, <http:\/\/www.ninds.nih.gov\/disorders\/neurofibromatosis\/detail_neurofibromatosis.htm> [accessed 27.09.13]."},{"key":"10.1016\/j.mehy.2015.01.014_b0010","unstructured":"Neurofibromatosis 1. Gene Reviews\u2122. <http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1109\/> [accessed 27.09.13]."},{"issue":"6","key":"10.1016\/j.mehy.2015.01.014_b0015","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s004390050287","article-title":"Sex differences in mutational rate and mutational mechanism in the NF1 gene in neurofibromatosis type 1 patients","volume":"98","author":"L\u00e1zaro","year":"1996","journal-title":"Hum Genet"},{"key":"10.1016\/j.mehy.2015.01.014_b0020","series-title":"The neurofibromatoses: a pathogenetic and clinical overview","author":"Huson","year":"1994"},{"issue":"3\u20134","key":"10.1016\/j.mehy.2015.01.014_b0025","first-page":"22","article-title":"Neurofibromatosis 1 prevalence in children aged 9\u201311years, Pinar del R\u00edo Province, Cuba","volume":"16","author":"Orraca","year":"2014","journal-title":"MEDICC Rev"},{"issue":"1","key":"10.1016\/j.mehy.2015.01.014_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<1::AID-AJMG3>3.0.CO;2-8","article-title":"Epidemiology of neurofibromatosis type 1","volume":"89","author":"Friedman","year":"1999","journal-title":"Am J Med Genet"},{"issue":"8","key":"10.1016\/j.mehy.2015.01.014_b0035","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/jmg.37.8.632","article-title":"Epidemiology of neurofibromatosis type 1 (NF1)in northern Finland","volume":"37","author":"Poyhonen","year":"2000","journal-title":"J Med Genet"},{"key":"10.1016\/j.mehy.2015.01.014_b0040","unstructured":"South African Neurofibromatosis Foundation. <http:\/\/doctors-hospitals-medical-cape-town-south-africa.blaauwberg.net\/patient_support_associations\/south_african_neurofibromatosis_association> [accessed 23.12.14]."},{"key":"10.1016\/j.mehy.2015.01.014_b0045","unstructured":"National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13\u201315, 1987. Neurofibromatosis. 1988;1(3):172-8. Review. PubMed PMID: 3152465."},{"key":"10.1016\/j.mehy.2015.01.014_b0050","unstructured":"NF1 neurofibromin 1 [ Homo sapiens (human)]. NCBI Gene. <http:\/\/www.ncbi.nlm.nih.gov\/gene\/4763> [accessed 27.09.13]."},{"key":"10.1016\/j.mehy.2015.01.014_b0055","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-genom-091212-153523","article-title":"The RASopathies","author":"Rauen","year":"2013","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.mehy.2015.01.014_b0060","unstructured":"Packer, Alan. RAS pathway, a potentially unifying theory of autism. Simons Foundation Autism Research Initiative. <http:\/\/sfari.org\/news-and-opinion\/directors-columns\/2012\/ras-pathway-a-potentially-unifying-theory-of-autism> [accessed 27.09.13]."},{"issue":"2","key":"10.1016\/j.mehy.2015.01.014_b0065","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajmg.a.33139","article-title":"Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service","volume":"152A","author":"Evans","year":"2010","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.mehy.2015.01.014_b0070","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/sj.ejhg.5201676","article-title":"Neurofibromatosis 1","volume":"15","author":"Ferner","year":"2007","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"10.1016\/j.mehy.2015.01.014_b0075","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000327557","article-title":"Neurofibromatosis without neurofibromas: confirmation of a genotype-phenotype correlation and implications for genetic testing","volume":"11","author":"Quint\u00e1ns","year":"2011","journal-title":"Case Rep Neurol"},{"key":"10.1016\/j.mehy.2015.01.014_b0080","doi-asserted-by":"crossref","DOI":"10.1136\/jmedgenet-2013-101648","article-title":"Can the diagnosis of NF1 be excluded clinically? A lack of pigmentary findings in families with spinal neurofibromatosis demonstrates a limitation of clinical diagnosis","author":"Burkitt Wright","year":"2013","journal-title":"J Med Genet"},{"issue":"3","key":"10.1016\/j.mehy.2015.01.014_b0085","first-page":"297","article-title":"Neurofibromin in neurofibromatosis type 1 \u2013 mutations in NF1gene as a cause of disease","volume":"18","author":"Abramowicz","year":"2014","journal-title":"Dev Period Med"},{"issue":"2\u20133","key":"10.1016\/j.mehy.2015.01.014_b0090","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0232-1513(83)80023-1","article-title":"Plexiform structures in malignant schwannomas after prenatal exposure to ethylnitrosourea","volume":"24","author":"Cardesa","year":"1983","journal-title":"Exp Pathol"},{"issue":"3","key":"10.1016\/j.mehy.2015.01.014_b0095","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/ajmg.a.34413","article-title":"The importance of advanced parental age in the origin of neurofibromatosis type 1","volume":"158A","author":"Snajderova","year":"2012","journal-title":"Am J Med Genet A"},{"issue":"1","key":"10.1016\/j.mehy.2015.01.014_b0100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S1028-4559(08)60049-2","article-title":"Syndromes, disorders and maternal risk factors associated with neural tube defects (II)","volume":"47","author":"Chen","year":"2008","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.mehy.2015.01.014_b0105","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-1-60327-492-0_5","article-title":"Parental smoking and childhood leukemia","volume":"472","author":"Chang","year":"2009","journal-title":"Methods Mol Biol"},{"issue":"6","key":"10.1016\/j.mehy.2015.01.014_b0110","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2340\/00015555-0938","article-title":"Local mast cell histamine and plasma histamine levels in neurofibromatosis type 1","volume":"90","author":"Yoshida","year":"2010","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"10.1016\/j.mehy.2015.01.014_b0115","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2009-09-242875","article-title":"Mast cells and the neurofibroma microenvironment","volume":"116","author":"Staser","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.mehy.2015.01.014_b0120","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s001090050259","article-title":"Clinical implications of mast cell-bacteria interaction","volume":"76","author":"Malaviya","year":"1998","journal-title":"J Mol Med (Berl)"},{"issue":"2","key":"10.1016\/j.mehy.2015.01.014_b0125","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1744-313X.2006.00579.x","article-title":"Serum IgE levels in neurofibromatosis 1","volume":"33","author":"Geller","year":"2006","journal-title":"Int J Immunogenet"},{"key":"10.1016\/j.mehy.2015.01.014_b0130","unstructured":"American Society of Human Genetics. Clinical Genetics and Dysmorphology Poster. <http:\/\/www.ichg2011.org\/cgi-bin\/showdetail.pl?absno=10061> [accessed 27.09.13]."},{"issue":"Suppl. 1","key":"10.1016\/j.mehy.2015.01.014_b0135","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1136\/thorax.55.suppl_1.S2","article-title":"Family size, infection and atopy: the first decade of the \u201chygiene hypothesis\u201d","volume":"55","author":"Strachan","year":"2000","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.mehy.2015.01.014_b0140","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12016-011-8285-8","article-title":"Hygiene hypothesis and autoimmune diseases","volume":"42","author":"Rook","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"10.1016\/j.mehy.2015.01.014_b0145","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.mehy.2011.06.019","article-title":"Reconstitution of the human biome as the most reasonable solution for epidemics of allergic and autoimmune diseases","volume":"77","author":"Bilbo","year":"2011","journal-title":"Med Hypotheses"},{"issue":"7423","key":"10.1016\/j.mehy.2015.01.014_b0150","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/491183a","article-title":"Autoimmunity: The worm returns","volume":"491","author":"Weinstock","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.mehy.2015.01.014_b0155","unstructured":"Weinstock, JV. <www.youtube.com\/watch?v=JpxMUwSOYQY> [accessed 30.08.12]."},{"key":"10.1016\/j.mehy.2015.01.014_b0160","first-page":"910946","article-title":"Is autism a member of a family of diseases resulting from genetic\/cultural mismatches? Implications for treatment and prevention","volume":"2012","author":"Bilbo","year":"2012","journal-title":"Autism Res Treat"},{"issue":"7","key":"10.1016\/j.mehy.2015.01.014_b0165","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1185\/03007995.2012.695731","article-title":"A prescription for clinical immunology: the pills are available and ready for testing. A review","volume":"28","author":"Parker","year":"2012","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"10.1016\/j.mehy.2015.01.014_b0170","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/1471-2148-10-264","article-title":"The landscape of human genes involved in the immune response to parasitic worms","volume":"31","author":"Fumagalli","year":"2010","journal-title":"BMC Evol Biol"},{"key":"10.1016\/j.mehy.2015.01.014_b0175","unstructured":"Coronado Biosciences. Research and Development Pipeline. <http:\/\/www.coronadobiosciences.com\/research-development\/pipeline.cfm> [accessed 27.09.13]."},{"issue":"1","key":"10.1016\/j.mehy.2015.01.014_b0180","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/oxfordjournals.aje.a010118","article-title":"NF1 gene and neurofibromatosis 1","volume":"151","author":"Rasmussen","year":"2000","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.mehy.2015.01.014_b0185","series-title":"Neurofibromatosis type 1 in childhood","author":"North","year":"1997"},{"issue":"1","key":"10.1016\/j.mehy.2015.01.014_b0190","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/gut.53.1.7","article-title":"Helminths and harmony","volume":"53","author":"Weinstock","year":"2004","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.mehy.2015.01.014_b0195","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/bja\/86.4.555","article-title":"Neurofibromatosis: clinical presentations and anaesthetic implications","volume":"86","author":"Hirsch","year":"2001","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.mehy.2015.01.014_b0200","unstructured":"Korf B et al. Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis. UpToDate. <http:\/\/www.uptodate.com\/contents\/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis> [accessed 23.12.14]."},{"issue":"11","key":"10.1016\/j.mehy.2015.01.014_b0205","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/jmg.31.11.853","article-title":"Neurofibromatosis type 1 in Israel: survey of young adults","volume":"31","author":"Garty","year":"1994","journal-title":"J Med Genet"},{"issue":"1","key":"10.1016\/j.mehy.2015.01.014_b0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mehy.2013.03.024","article-title":"Possible use of Trichuris suis ova in autism spectrum disorders therapy","volume":"81","author":"Siniscalco","year":"2013","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.mehy.2015.01.014_b0215","unstructured":"Trichuris Suis Ova in Autism Spectrum Disorders (TSO). Clinical trial. <http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01040221> [accessed 27.09.13]."},{"key":"10.1016\/j.mehy.2015.01.014_b0220","unstructured":"TSO in Pediatric Autistic Spectrum Disorders. Clinical trial. <http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01734941> [accessed 27.09.13]."},{"key":"10.1016\/j.mehy.2015.01.014_b0225","unstructured":"Tanawisa Company News, 20-05-2014. <http:\/\/www.tanawisa.com\/index.php\/news> [accessed 24.12.14]."},{"issue":"6","key":"10.1016\/j.mehy.2015.01.014_b0230","doi-asserted-by":"crossref","first-page":"e1642","DOI":"10.1542\/peds.2013-1868","article-title":"Neurofibromatosis type 1 and autism spectrum disorder","volume":"132","author":"Garg","year":"2013","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.mehy.2015.01.014_b0235","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/ajmg.b.32280","article-title":"Prevalence of Autism Spectrum Disorder symptoms in children with neurofibromatosis type 1","volume":"168","author":"Plasschaert","year":"2015","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"6","key":"10.1016\/j.mehy.2015.01.014_b0240","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10787-010-0054-4","article-title":"The sad plight of multiple sclerosis research (low on fact, high on fiction): critical data to support it being a neurocristopathy","volume":"18","author":"Behan","year":"2010","journal-title":"Inflammopharmacology"},{"issue":"3","key":"10.1016\/j.mehy.2015.01.014_b0245","first-page":"747","article-title":"Genetic markers and animal models of neurocristopathy","volume":"10","author":"Nakamura","year":"1995","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.mehy.2015.01.014_b0250","unstructured":"Parker W. The potential role of fauna and flora disruption in the human body as constituents to the development of autism. Presented at: Microbiome in Autism Conference, Arkansas Children\u2019s Hospital, 2014. <http:\/\/media.archildrens.org\/Mediasite\/Play\/c5241df9f63e49caa42ce2e86edf26ae1d> [accessed 23.12.14]."},{"issue":"1\u20132","key":"10.1016\/j.mehy.2015.01.014_b0255","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jns.2009.04.039","article-title":"Environmental changes and epidemiology of multiple sclerosis in the French West Indies","volume":"286","author":"Cabre","year":"2009","journal-title":"J Neurol Sci"},{"issue":"3\u20134","key":"10.1016\/j.mehy.2015.01.014_b0260","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ijpara.2012.10.025","article-title":"Helminth therapy and multiple sclerosis","volume":"43","author":"Fleming","year":"2013","journal-title":"Int J Parasitol"},{"issue":"14","key":"10.1016\/j.mehy.2015.01.014_b0265","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1745-6215-14-112","article-title":"Trichuris suis ova in relapsing-remitting multiple sclerosis and clinically isolated syndrome (TRIOMS): study protocol for a randomized controlled trial","volume":"25","author":"Rosche","year":"2013","journal-title":"Trials"},{"issue":"3","key":"10.1016\/j.mehy.2015.01.014_b0270","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1620\/tjem.217.193","article-title":"Tranilast, an anti-allergic drug, down-regulates the growth of cultured neurofibroma cells derived from neurofibromatosis type 1","volume":"217","author":"Yamamoto","year":"2009","journal-title":"Tohoku J Exp Med"},{"issue":"5","key":"10.1016\/j.mehy.2015.01.014_b0275","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/archderm.1993.01680260047004","article-title":"A controlled multiphase trial of ketotifen to minimize neurofibroma-associated pain and itching","volume":"129","author":"Riccardi","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.mehy.2015.01.014_b0280","unstructured":"A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas (Protocol 102). Clinical trial. <http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00634270> [accessed 27.09.13]."},{"key":"10.1016\/j.mehy.2015.01.014_b0285","unstructured":"Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas (NFitor). Clinical trial. <http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01412892> [accessed 27.09.13]."},{"key":"10.1016\/j.mehy.2015.01.014_b0290","unstructured":"Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1) (MACS0977), Clinical trial. <http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01365468> [accessed 27.09.13]."},{"key":"10.1016\/j.mehy.2015.01.014_b0295","unstructured":"Maldonado RA, von Andrian UH. How tolerogenic dendritic cells induce regulatory T cells. NIH Public Access. <http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3050492\/> [accessed 27.09.13]."},{"key":"10.1016\/j.mehy.2015.01.014_b0300","unstructured":"Kane CM. Helminth antigens modulate TLR-ligand induced dendritic cell activation. ScholarlyCommons: Repository, Upenn Library. <http:\/\/repository.upenn.edu\/dissertations\/AAI3260927\/> [accessed 27.09.13]."},{"key":"10.1016\/j.mehy.2015.01.014_b0305","article-title":"Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation","author":"Somers","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.mehy.2015.01.014_b0310","unstructured":"Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas. Clinical trial. <http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00030264> [accessed 27.09.13]."},{"key":"10.1016\/j.mehy.2015.01.014_b0315","unstructured":"Lawton P. Purine analogues as antiparasitic agents. Mendelay. <http:\/\/www.mendeley.com\/research\/purine-analogues-as-antiparasitic-agents\/>, [accessed 27.09.13]."},{"issue":"4","key":"10.1016\/j.mehy.2015.01.014_b0320","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1128\/CMR.17.4.1012-1030.2004","article-title":"Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy","volume":"17","author":"Borkow","year":"2004","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"10.1016\/j.mehy.2015.01.014_b0325","doi-asserted-by":"crossref","first-page":"e2880","DOI":"10.1371\/journal.pntd.0002880","article-title":"Helminth colonization is associated with increased diversity of the gut microbiota","volume":"8","author":"Lee","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.mehy.2015.01.014_b0330","unstructured":"Thornton, J. The New (Ancient) Cure for Immune Disorders. Men\u2019s Health. <http:\/\/challenge.menshealth.com\/print\/37290>; 2012 [accessed 16.07.14]."},{"issue":"10","key":"10.1016\/j.mehy.2015.01.014_b0335","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri1460","article-title":"Mast-cell responses to pathogens","volume":"4","author":"Marshall","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.mehy.2015.01.014_b0340","first-page":"208","article-title":"Study of the mastocytes in Recklinghausen\u2019s neurogliomatosis","volume":"102","author":"Binazzi","year":"1961","journal-title":"G Ital Dermatol"},{"issue":"4","key":"10.1016\/j.mehy.2015.01.014_b0345","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/MOH.0b013e328339511b","article-title":"Plexiform neurofibroma genesis: questions of Nf1 gene dose and hyperactive mast cells","volume":"17","author":"Staser","year":"2010","journal-title":"Curr Opin Hematol"},{"issue":"6","key":"10.1016\/j.mehy.2015.01.014_b0350","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1369\/0022155411407340","article-title":"Different patterns of mast cells distinguish diffuse from encapsulated neurofibromas in patients with neurofibromatosis 1","volume":"59","author":"Tucker","year":"2011","journal-title":"J Histochem Cytochem"},{"issue":"6","key":"10.1016\/j.mehy.2015.01.014_b0355","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.2353\/ajpath.2010.100369","article-title":"Nf1-\/- Schwann cell-conditioned medium modulates mast cell degranulation by c-Kit-mediated hyperactivation of phosphatidylinositol 3-kinase","volume":"177","author":"Chen","year":"2010","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.mehy.2015.01.014_b0360","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.yexmp.2014.02.006","article-title":"Do mast cells play a pathogenetic role in neurofibromatosis type 1 and ulcerative colitis?","volume":"96","author":"Baratelli","year":"2014","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.mehy.2015.01.014_b0365","unstructured":"Theoharides T. \u2018Brain Allergy\u2019 and ASD. Autism Research Institute, 2013. <http:\/\/www.youtube.com\/watch?v=9QbZp3WcC1Q&feature=youtu.be> [accessed 16.07.14]."},{"key":"10.1016\/j.mehy.2015.01.014_b0370","doi-asserted-by":"crossref","DOI":"10.1111\/aji.12234","article-title":"Immunological modes of pregnancy loss: inflammation, immune effectors, and stress","author":"Kwak-Kim","year":"2014","journal-title":"Am J Reprod Immunol"},{"issue":"5","key":"10.1016\/j.mehy.2015.01.014_b0375","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/ijc.2910560507","article-title":"Foetal loss and infant deaths in families of children with soft-tissue sarcoma","volume":"56","author":"Hartley","year":"1994","journal-title":"Int J Cancer"},{"key":"10.1016\/j.mehy.2015.01.014_b0380","doi-asserted-by":"crossref","DOI":"10.1111\/pim.12101","article-title":"Pregnancy and helminth infections","author":"Mpairwe","year":"2014","journal-title":"Parasite Immunol"},{"issue":"9936","key":"10.1016\/j.mehy.2015.01.014_b0385","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(13)61901-7","article-title":"Myelodysplastic syndromes","volume":"383","author":"Ad\u00e8s","year":"2014","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.mehy.2015.01.014_b0390","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1186\/1471-2164-14-473","article-title":"MicroRNAome profiling in benign and malignant neurofibromatosis type 1-associated nerve sheath tumors: evidences of PTEN pathway alterations in early NF1 tumorigenesis","volume":"13","author":"Masliah-Planchon","year":"2013","journal-title":"BMC Genomics"},{"issue":"1","key":"10.1016\/j.mehy.2015.01.014_b0395","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3901\/JME.2013.17.101","article-title":"Mammalian target of rapamycin inhibitor abrogates abnormal osteoclastogenesis in neurofibromatosis type 1","volume":"126","author":"Liu","year":"2013","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.mehy.2015.01.014_b0400","series-title":"Neurofibromatosis type 1: molecular and cellular biology","author":"Upadhyaya","year":"2012"},{"key":"10.1016\/j.mehy.2015.01.014_b0405","doi-asserted-by":"crossref","DOI":"10.4303\/jem\/Q120503","article-title":"Immune characterization of wild-caught rattus norvegicus suggests diversity of immune activity in biome-normal environments","volume":"1","author":"Lin","year":"2012","journal-title":"J Evol Med"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987715000353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987715000353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T02:24:20Z","timestamp":1537928660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987715000353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":81,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0306987715000353"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2015.01.014","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biome depletion in conjunction with evolutionary mismatches could play a role in the etiology of neurofibromatosis 1","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2015.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}